IP Library Patent Application 17122333
Patent Application
App. No. 17/122,333

HUMANIZED ANTI-BAG3 ANTIBODIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/122,333
Abstract

The present invention provides for a humanized anti-BAG3 antibody or a fragment thereof, pharmaceutical compositions comprising said antibody and its use as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic, cardiovascular and/or degenerative nature.

Claims (12)

1 . A humanized antibody or a fragment thereof which binds to the BAG3 protein, comprising:

a) a heavy chain having the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having at least 95% sequence identity thereof,

b) a light chain having the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence having at least 95% sequence identity thereof.

2 . The humanized antibody or a fragment thereof according to claim 1 , which is a Fab fragment, a Fab′ fragment, a F(ab′) fragment, a Fv fragment, a diabody, a ScFv, a small modular immunopharmaceutical (SMIP), an affibody, an avimer, a nanobody, a domain antibody, or single chains.

3 . A nucleic acid encoding the antibody or a fragment thereof according to claim 1 .

4 . A vector comprising the nucleic acid according to claim 3 .

5 . A host cell comprising the nucleic acid of claim 3 .

6 . A pharmaceutical composition comprising at least one antibody or a fragment thereof according to claim 1 and at least one pharmaceutically acceptable excipient or carrier.

7 . The pharmaceutical composition according to claim 6 , in a form of oral formulation, parenteral formulation, or topical administration.

8 . The pharmaceutical composition according to claim 6 , further comprising antimetabolites, camptothecins, or taxanes.

9 . A method for treating a pathological state which involves the activation of macrophages, selected from the group consisting of: neoplastic diseases, inflammatory diseases, immune diseases and degenerative diseases, comprising administering the humanized antibody or a fragment thereof according to claim 1 to a subject in need thereof.

10 . The method according to claim 9 , for treating pancreatic tumor or bladder tumor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2022
From: BIOUNIVERSA S.R.L.
To: FIBROSYS S.R.L.
Reel/Frame 061141/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2022
From: TURCO, MARIA CATERINA; ROSATI, ALESSANDRA; DE LAURENZI, VINCENZO; SALA, GIANLUCA
To: BIOUNIVERSA S.R.L.
Reel/Frame 061126/0246 →